249 related articles for article (PubMed ID: 22054733)
1. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.
Jain N; van Besien K
Hematol Oncol Clin North Am; 2011 Oct; 25(5):1025-48, vi. PubMed ID: 22054733
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
3. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Velev N; Cortes J; Champlin R; Jones D; Rondon G; Giralt S; Borthakur G; Kantarjian HM; De Lima M
Cancer; 2010 Aug; 116(15):3631-7. PubMed ID: 20564073
[TBL] [Abstract][Full Text] [Related]
4. Stem cell transplant for chronic myeloid leukemia in the imatinib era.
Radich J
Semin Hematol; 2010 Oct; 47(4):354-61. PubMed ID: 20875552
[TBL] [Abstract][Full Text] [Related]
5. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
Goldman J
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic myeloid leukemia with imatinib mesylate.
Ohno R
Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Jabbour E; Kantarjian H; Jones D; Breeden M; Garcia-Manero G; O'Brien S; Ravandi F; Borthakur G; Cortes J
Blood; 2008 Jul; 112(1):53-5. PubMed ID: 18403620
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S; Lauseker M; Gratwohl A; Beelen DW; Bunjes D; Schwerdtfeger R; Kolb HJ; Ho AD; Falge C; Holler E; Schlimok G; Zander AR; Arnold R; Kanz L; Dengler R; Haferlach C; Schlegelberger B; Pfirrmann M; Müller MC; Schnittger S; Leitner A; Pletsch N; Hochhaus A; Hasford J; Hehlmann R;
Blood; 2010 Mar; 115(10):1880-5. PubMed ID: 19965667
[TBL] [Abstract][Full Text] [Related]
10. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
11. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Zhao Y; Luo Y; Shi J; Cai Z; Huang H
Am J Med Sci; 2014 Jun; 347(6):439-45. PubMed ID: 24553398
[TBL] [Abstract][Full Text] [Related]
12. Front-line TKI therapy for chronic-phase CML: the luxury of choice.
Shah NP
Oncology (Williston Park); 2012 Oct; 26(10):908, 910, 912. PubMed ID: 23175996
[No Abstract] [Full Text] [Related]
13. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.
Dufies M; Cassuto O; Jacquel A; Robert G; Auberger P
Cell Cycle; 2013 Jun; 12(11):1645-6. PubMed ID: 23673326
[No Abstract] [Full Text] [Related]
15. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.
Giralt S
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S102-4. PubMed ID: 17382018
[TBL] [Abstract][Full Text] [Related]
17. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
18. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Zhang WW; Cortes JE; Yao H; Zhang L; Reddy NG; Jabbour E; Kantarjian HM; Jones D
J Clin Oncol; 2009 Aug; 27(22):3642-9. PubMed ID: 19506164
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
20. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]